OncoMatch/Clinical Trials/NCT04980716
Early Specialized Cardiovascular Intervention Based on Impedance Cardiography in Locally Advanced Non-small Cell Lung Cancer Patients
Is NCT04980716 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Multiple cardiovascular drugs related to "Golden Triangle" for non-small cell lung cancer.
Treatment: Multiple cardiovascular drugs related to "Golden Triangle" — This is a prospective, randomized, controlled, multi-center phase III clinical trial that intends to evaluate the role of early cardiovascular intervention based on impedance cardiography in patients with locally advanced non-small cell lung cancer receiving radical radiochemotherapy±immunotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage III
Performance status
WHO 0–1
Lab requirements
Blood counts
absolute neutrophil count ≥1.5×10^9/L; platelets ≥100×10^9/L; hemoglobin ≥90 g/L
Kidney function
serum creatinine clearance calculated according to the Cockcroft-Gault formula ≥50 mL/min
Liver function
serum bilirubin ≤1.5 times ULN; alanine aminotransferase and aspartate aminotransferase ≤2.5 times ULN
Cardiac function
FEV1 ≥1000 ml
Organ and bone marrow function meet the following conditions: Forced expiratory volume per second (FEV1) ≥1000 ml; absolute neutrophil count ≥1.5×10^9/L; platelets ≥100×10^9/L; hemoglobin ≥90 g/L ; Serum creatinine clearance calculated according to the Cockcroft-Gault formula ≥50 mL/min (Cockcroft and Gault 1976); serum bilirubin ≤1.5 times the upper limit of normal (ULN); alanine aminotransferase and aspartate aminotransferase ≤2.5 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify